AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05544370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extensive high-intensity intervallic training
Description: The extensive high-intensity intervallic training group performs 3 sets of 120 seconds of work and 120 seconds of rest at an intensity of 70-75% of the reserve heart rate during the work phase and an intensity of 50-55% of the reserve heart rate during the rest phase. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 80-85% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.
Study NCT06063772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine
Description: The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90 seconds to a maximum rate 32 mg/hr for clevidipine or the volume equivalent of placebo.
Study NCT06063772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringers, Intravenous
Description: The investigator will start the appropriate drug and titrate the drug in the pre-operative area until the mean arterial pressure is between 70 mmHg and 110 mmHg. The infusion will be titrated every 90s to a maximum rate 32mg/hr for clevidipine or the volume equivalent of placebo.
Study NCT05078827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product (A): Fluorouracil Cream, 5% topical cream
Description: Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
Study NCT05078827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.
Description: Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
Study NCT05078827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
Description: Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
Study NCT04804839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First research arm
Description: Patients in this group were given 8-week PFMT (including knack maneuver) and lifestyle recommendations for the treatment of urinary incontinence symptoms.
Study NCT04804839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second research arm
Description: Patients in this group were given only 8-week PFMT (including knack maneuver) for the treatment of urinary incontinence symptoms.
Study NCT04804839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Third research arm
Description: It is the control group and patients in this group were given alone8-week PFMT (without knack maneuver).
Study NCT06641622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prediction of delayed graft function
Description: Donor plasma CIRBP levels were measured using an ELISA kit to evaluate their association with DGF incidence
Study NCT06638125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping
Description: All patients in Phase I and those randomized to Intervention in Phase II will have preoperative 3D VR reconstructions of their pulmonary anatomy with the target lesion created using the Elucis platform. Segment identification and confidence rating will be collected before and after visualizing the 3D VR reconstruction. Intraoperatively, the surgeon will use this 3D VR model as a guide to determine which inflow and outflow vessels to the involved segment need to be removed. After vascular ligation, a 8mL bolus of ICG solution will be injected into a peripheral vein catheter by anesthesia. The surgeon will mark out the segmental plane based on the fluorescence pattern seen on the infrared mode of the robotic camera. The surgeon will then perform the pulmonary resection and the resected non-fluorescent lung segment will be extracted from the body cavity. Study patients will receive routine postoperative care as non-study patients and will be followed until the 3-4-week mark.
Study NCT06638125 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping
Description: The patients that are randomized to Control in Phase II will undergo the same intervention as above, but instead of using Elucis for 3D VR reconstructions, Synapse 3D will be used for 3D reconstructions.
Study NCT06415942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Outcome Monitoring and Support system
Description: The Maternal Outcome Monitoring and Support system is a mobile health application that allows participants to choose symptoms they may be having that are warning signs of pregnancy related death. They then receive decision support about when they should seek medical care (call their provider or go to an emergency room).
Study NCT06326424 — intervention group
Intervention type: DEVICE
Intervention: Empatica EmbracePlus
Description: wear a biosensor watch to passively collect biosensor data over 48 hours. The EmbracePlus will collect heart rate variability, accelerometry, and electrodermal activity.
Study NCT06637228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move Your Hands, Feet, and Brain: Integrated Exercise Intervention Based on Taipei City Elderly Physical Activity Guidelines
Description: This video is tailored for fitness exercises for both healthy and sub-healthy elderly individuals and features various physical activity themes, including warm-up routines, balance and coordination drills, aerobic coordination exercises, strength training using chairs and water bottles, and cool-down routines. We selected a 3-month duration with sessions held three times a week to align with established effective intervention periods and to ensure participant adherence.~Integrated exercise sessions were conducted by the staff at the dementia care centers/service bases and lasted 50 minutes. Considering the impact of dementia and aging on the ability of older adults to engage in physical activities, the staff provided simple instructions, and participants performed the exercises while seated to prevent falls. Meanwhile, the control group continued with their usual treatment and daily activities.
Study NCT06640803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped-Care including Cognitive Behavioral Case Management
Description: Step 1:assessment and feedback, general engagement strategies, assessment of needs and social determinants of health, begin case management, goal setting. Step 2: TAU. Initiation of team-based care at community clinics and 'enhanced monitoring'. Step 3: atheoretically-based stress management skills (stress thermometer, coping skills and coping plans), problem solving strategies. Step 4: targeted intervention for CHRp. Initiation of formulation-based CBT modules, therapy consultation groups with the UC Davis team (UCD), regular meetings between clinic leadership and UCD. Participants may switch providers to increase level of early psychosis specialization. Step 5: add prescriber consultation groups with UCD. Step 6: assessment of trauma and family conflict then Family-Focused Therapy, Trauma-Focused Cognitive Behavioral Therapy, or CBT for CHR at UCD. Termination: At 24 months, referral to UCD coordinated specialty care clinic or other appropriate service for those still CHRp+.
Study NCT06636903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Before pressing directly on the point for acupressure, a gentle warming, relaxing and preparatory process of approximately 15 seconds should be performed on the point area. In this case, manual pressure with the thumb, index finger and/or middle finger will be applied sequentially (in the rhythm of breathing) without lifting the finger for an average of 1.5 minutes on each point, at a frequency that does not disturb the person, does not cause pain and has a calming effect. Before the suturing procedure, acupressure will be applied to the HT7 and Li4 points by a researcher (EB) who has an acupressure certificate.
Study NCT06636903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Before and after acupressure, vital signs and before acupressure, anxiety scores will be checked using the Spielger State Anxiety Scale. In addition, vital signs and anxiety scores will be checked again immediately after the stitching procedure.
Study NCT06639932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: We-INtervention
Description: The We-INtervention focuses on the relationship dynamics of HIV-serodiscordant male couples. In developing the intervention, we reviewed relevant theories and frameworks, such as the cognitive transactional model, the systemic transactional model, the dyadic illness management model, and the intersectional framework of stigma. The three weekly 60-minute sessions are Session 1: We-disease appraisal. Despite stigma related to their dual minority identities, couples develop a perception of HIV as a shared disease, enhancing illness control. Session 2: Couple communication. Couples undertake skill-building exercises on effective communication techniques to strengthen their relationship. Session 3: Dyadic coping. Couples learn to optimize preference and value assessments in HIV management. A few skill-building exercises help them mobilize and maintain mutual support and develop joint problem-solving skills.
Study NCT06639932 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: The participants in the control condition will receive health information pamphlets. The HIV-seropositive partners will receive information on HIV-related knowledge (e.g., symptoms, comorbidity, stages, and opportunistic infection), treatment (e.g., ART and side effects), and management (e.g., nutrition and mental health). The HIV-seronegative partner will receive information on HIV transmission (e.g., risk factors), prevention (e.g., safe sex and PrEP), and testing.
Study NCT06564363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IUrisure test
Description: Postoperative patients are followed up every three months on average, and IUrisure test was performed at each follow-up visit.
Study NCT06170242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-323 Dose Regimen 1
Description: EDP-323 capsule
Study NCT06170242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-323 Dose Regimen 2
Description: EDP-323 capsule
Study NCT06170242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT05501522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBP510 adjuvanted with AS03
Description: injection volume of 0.5mL on Day 0
Study NCT05501522 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GBP510 adjuvanted with AS03
Description: injection volume of 0.5mL on Day 0
Study NCT05488119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to increase diabetes technology uptake
Description: The design for this phase is a prospective pilot study. The intervention modules will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will also evaluate youth diabetes management and technology use. Families will be compensated in a stepwise fashion. Virtual delivery of the pilot intervention will facilitate national recruitment and allow for recruitment during the pandemic or any ensuing limitations to in-person recruitment. I will recruit 20 families or providers to participate in the delivery of the pilot intervention designed in Phase 1 of the study via a stakeholder advisory board.
Study NCT05501522 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal Saline)
Description: injection volume of 0.5mL on Day 0
Study NCT05191745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parasternal blocks
Description: Parasternal block with Bupivacaine 0.25% + Epinephrine 1:200,000 x 60cc + Dexamethasone 5mg and Dexmedetomidine 50mcg
Study NCT05191745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: All standard management of postoperative pain, as per local protocols
Study NCT05870111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline (cytidine diphosphate-choline)
Description: 2000mg/day citicoline, administered orally, for 4 weeks
Study NCT05870111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: placebo capsule daily for 4 weeks, matched in appearance to citicoline to preserve double-blind, administered orally
Study NCT06031402 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: Endoscopy
Study NCT06031402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Endoscopy
Study NCT05300607 — intervention group
Intervention type: OTHER
Intervention: Cross-cultural adaptation, validity, and reliability
Description: evaluation, translation, cultural adaption, validation, and investigation of the reliability of Arabic version of The Western Ontario Rotator Cuff Index (WORC) to be used in Arabic countries.
Study NCT05059626 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: simvastatin 10mg
Description: Simvastation acts as a systemic LOX inhibitor.
Study NCT06030310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The developmental Exercise Programme of INPP
Description: The INPP school motor program consists of a series of developmental movements based on the normal movements of a child in their first year of life. Exercises must be performed as slow as possible and must be repeated for at least six weeks.~Once the children have performed a set of movements, a new set will be presented for practice in a more complex position.~The exercises are done on the floor and aid in developing:~Proper alignment of the head with the body, trunk stability. Balance and coordination. The ability to use both sides of the body and upper and lower parts independently.~Muscle tone in prone and supine position. Hand-eye coordination and visual skills
Study NCT05860335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Nedaplatin, albumin paclitaxel
Description: During induction chemotherapy, triplelimab JS001 was administered before cisplatin/Nedaplatin and albumin paclitaxel. JS001 Intravenous infusion of cisplatin/Nedaplatin was administered 60 minutes after the end of infusion and beginning on day 1 of each cycle 40mg/m 2, D1, D2 albumin paclitaxel 230 mg/m 2; Chemotherapeutic drugs are administered in accordance with the drug label and local prodrome and other standard protocols for prophylactic use, every 3 Once a week (Q3W) for 2 cycles
Study NCT05736783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric exercises
Description: 1. st week Wall touches 3x30 s Split squat jumps 2x40 Lateral cone jumps 2x30 Cone hops with 180 turn 4conesx10~2. nd week Wall touches 4x30 s Split squat jumps 2x40 Lateral cone jumps 2x30 Cone hops with 180 turn 4 cones x 30~3. rd week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30~4. th week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30 Drop jump 45.72 cm 45.72 cm (20)~5. th week Wall touches 5x30 s Split squat jumps 2x60 Lateral cone jumps 2x50 Cone hops with 180 turn 4 cones x 30 Drop jump 45.72 cm 45.72 cm (30)~6. th week Wall touches 6x30 s Split squat jumps 2x70 Lateral cone jumps 2x60 Cone hops with 180 turn 4 cones x 40 Drop jump 45.72 cm (40)
Study NCT05736783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strenghtening of quadriceps and hamstring
Description: 1st to 3rd week l 4th to 6th week Squat 2x12 3x8 l 3x10 4x6 Knee extension 3x12 3x8 l 2x10 2x6 Nordic hamstring 3x3 3x3 l 3x4 3x4
Study NCT04926077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreamKit
Description: The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing; however, this study is intended only to validate the respiratory effort signal and does not assess diagnostic performance.
Study NCT05059626 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bazedoxifene 20/Estrogens,Con 0.45Mg Tb
Description: Duavee is a selective estrogen receptor modulator.
Study NCT04478890 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hemodynamic assessment
Description: Hemodynamic assessment of the right ventricle using pressure-volume loop catheter and pulmonary artery catheter
Study NCT04665180 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Primary knee arthroplasty
Description: Patients who return to work after primary knee arthroplasty
Study NCT05939388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Acupressure Pads
Description: Pads containing seeds that are placed on specific sites of the ear that are thought to help with pain.
Study NCT05470985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specific dose on specific days
Study NCT06533735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Web
Description: Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
Study NCT06533735 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parent Web
Description: Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
Study NCT05825755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vitalera telemonitoring platform
Description: Patients will be followed-up with measurements from medical devices and health questionnaires delivered through the app
Study NCT06357377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEO100
Description: NEO100 is a purified form (>98.5%) of the naturally occurring monoterpene perillyl alcohol.~NEO100 drug product is a non-sterile solution for intranasal administration. It is compounded as a 10% solution in a 50:50 mixture of ethanol:glycerol.
Study NCT04163081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit Card Intervention (QCI)
Description: The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a Quit Card (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist.
Study NCT05632601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET scan
Description: PET scan
Study NCT06175533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided 60 degree CRF for plantar fasciitis
Description: ultrasound guided plantar fascia CRF for chronic conditions not responding to treatment
Study NCT05715333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 Injection
Study NCT05715333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection
Study NCT05242276 — intervention group
Intervention type: DEVICE
Intervention: USE OF UTERINE MANIPULATOR DURING THE HYSTERECTOMY
Description: The uterine manipulator is a device commonly used in minimally invasive hysterectomy surgery for endometrial cancer. However, without substantial evidence to support its use, surgeons are required to make decisions about its use based only on their personal choice and surgical experience. . It is inserted vaginally through the cervical canal into the endometrial cavity. The uterine manipulator facilitates the uterus mobilization during the surgery, generating tension on the main supporting elements of the uterus to improve surgical field exposure and provide a landmark for the colpotomy.
Study NCT06414096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follicle Stimulating Hormone
Description: Pulsatile FSH administration via a portable pump.
Study NCT06414096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone
Description: Pulsatile FSH administration via a portable pump.
Study NCT06190353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An internet-based self-help program with minimal telephone support utilizing Acceptance and Commitment Therapy for alleviating burnout among healthcare workers.
Description: An eight module self help program
Study NCT05660850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-6599
Description: GDC-6599 will be administered Days 1- 14 and on Days 29-42 as film-coated tablets